Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. held its Annual General Meeting on May 28, 2025, where all proposed resolutions were passed. Key resolutions included the re-election of board members, the re-appointment of Ernst & Young as auditors, and granting mandates for share issuance and repurchase. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational efficiency.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.13 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, focusing on the development, production, and sale of innovative medications. The company operates in the healthcare industry, providing a range of pharmaceutical products to meet diverse medical needs.
Average Trading Volume: 43,565,274
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.43B
Learn more about 2186 stock on TipRanks’ Stock Analysis page.